Category: allogeneic
Atara Biotherapeutics’ tabelecleucel (tab-cel) has become the first ‘allogeneic’ cell therapy – in other words one which doesn’t involve harvesting cells from patients – to be evaluated by a regulatory agency anywhere in the world. The EMA has started a review of the off-the-shelf therapy as a treatment for patients with a rare form of […]
The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival in patients with non-small cell lung cancer (NSCLC), sending the biotech’s share price skywards. Interim data from a phase 2 trial of Heat’s off-the-shelf cell therapy with Opdivo (nivolumab) showed that patients treated with the duo as […]
Accelerate the Bench to Bedside Development of Novel CAR Immunotherapies for Safe, Effective & Affordable Advanced Therapies With CAR-TCR therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Summit Europe (16th-18th February 2021) will unravel […]